Non ST elevation myocardial infarction pathophysiology: Difference between revisions
Jump to navigation
Jump to search
mNo edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
{{ | __NOTOC__ | ||
{{CMG}} | {{Unstable angina / NSTEMI}} | ||
{{CMG}}; '''Associate Editor-In-Chief:''' [[Varun Kumar]], M.B.B.S.; [[Lakshmi Gopalakrishnan]], M.B.B.S. | |||
'''Associate Editor-In-Chief:''' [[Varun Kumar]], M.B.B.S.; [[Lakshmi Gopalakrishnan]], M.B.B.S. | |||
==NSTEMI Background== | ==NSTEMI Background== | ||
| Line 13: | Line 10: | ||
This video shows [[plaque rupture]] or disruption of the [[atherosclerotic plaque]] in the mid [[LAD]]. As is often the case, the plaque has torn at its edge, a location where the [[fibrous cap]] covering the atherosclerotic plaque is the thinnest. Clot has formed and it is embolizing downstream. The most common preceding pathophysiologic event in NSTEMI is the disruption of an [[Atherosclerosis|atherosclerotic]] [[Atheroma|plaque]] in an epicardial [[coronary artery]] such as that shown here. Exposure of the atherosclerotic plaque contents to the blood stream leads to activation of the [[clotting cascade]], local thrombus formation, and incomplete occlusion of the epicardial artery in NSTEMI. This artery is open, in [[NSTEMI]] unlike [[STEMI]] where the artery is closed. The downstream microvasculature is occluded by the clot that has embolized, and this accounts for the [[troponin]] elevation in this patient. | This video shows [[plaque rupture]] or disruption of the [[atherosclerotic plaque]] in the mid [[LAD]]. As is often the case, the plaque has torn at its edge, a location where the [[fibrous cap]] covering the atherosclerotic plaque is the thinnest. Clot has formed and it is embolizing downstream. The most common preceding pathophysiologic event in NSTEMI is the disruption of an [[Atherosclerosis|atherosclerotic]] [[Atheroma|plaque]] in an epicardial [[coronary artery]] such as that shown here. Exposure of the atherosclerotic plaque contents to the blood stream leads to activation of the [[clotting cascade]], local thrombus formation, and incomplete occlusion of the epicardial artery in NSTEMI. This artery is open, in [[NSTEMI]] unlike [[STEMI]] where the artery is closed. The downstream microvasculature is occluded by the clot that has embolized, and this accounts for the [[troponin]] elevation in this patient. | ||
As opposed to the original hypothesis that [[acute coronary syndrome]] (ACS) is caused by gradual progression of coronary atherosclerosis to the point of a severe, fixed lesion, it has become clear that, in fact, ACS is usually caused by atherosclerotic plaque rupture at a site that previously had only mild to moderate stenosis.<ref name="pmid17100031">{{cite journal |author=Martinez-Rumayor A, Januzzi JL |title=Non-ST segment elevation acute coronary syndromes: A comprehensive review |journal=[[Southern Medical Journal]] |volume=99 |issue=10 |pages=1103–10 |year=2006 |month=October |pmid=17100031 |doi= |url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0038-4348&volume=99&issue=10&spage=1103 |accessdate=2011-04-11}}</ref> This plaque rupture exposes ligands (including collagen) for platelet adhesion which causes platelet aggregation and subsequent platelet activation. <ref name="pmid9296464">{{cite journal |author=Patrono C, Renda G |title=Platelet activation and inhibition in unstable coronary syndromes |journal=[[The American Journal of Cardiology]] |volume=80 |issue=5A |pages=17E–20E |year=1997 |month=September |pmid=9296464 |doi= |url= |accessdate=2011-04-11}}</ref> [[Platelets]] are activated by [[thrombin]] (found in blood clots), [[adenosine diphosphate]] (found in platelet granules), [[serotonin]] (also found in platelet granules) and thromboxane-A2. <ref name="pmid9296464">{{cite journal |author=Patrono C, Renda G |title=Platelet activation and inhibition in unstable coronary syndromes |journal=[[The American Journal of Cardiology]] |volume=80 |issue=5A |pages=17E–20E |year=1997 |month=September |pmid=9296464 |doi= |url= |accessdate=2011-04-11}}</ref> Upon activation, the [[glycoprotein IIb/IIIa]] receptor that in a non-active state is found in the cytosol is exteriorized and modified which enables additional platelet aggregation and cross-linking.<ref name="pmid17100031">{{cite journal |author=Martinez-Rumayor A, Januzzi JL |title=Non-ST segment elevation acute coronary syndromes: A comprehensive review |journal=[[Southern Medical Journal]] |volume=99 |issue=10 |pages=1103–10 |year=2006 |month=October |pmid=17100031 |doi= |url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0038-4348&volume=99&issue=10&spage=1103 |accessdate=2011-04-11}}</ref> The prothrombinase complex then binds to the activated platelet and starts to [[coagulation cascade]].<ref name="pmid17100031">{{cite journal |author=Martinez-Rumayor A, Januzzi JL |title=Non-ST segment elevation acute coronary syndromes: A comprehensive review |journal=[[Southern Medical Journal]] |volume=99 |issue=10 |pages=1103–10 |year=2006 |month=October |pmid=17100031 |doi= |url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0038-4348&volume=99&issue=10&spage=1103 |accessdate=2011-04-11}}</ref> This entire process results in a thrombus which coalesces over the ruptured plaque. | As opposed to the original hypothesis that [[acute coronary syndrome]] (ACS) is caused by gradual progression of coronary atherosclerosis to the point of a severe, fixed lesion, it has become clear that, in fact, ACS is usually caused by atherosclerotic plaque rupture at a site that previously had only mild to moderate stenosis.<ref name="pmid17100031">{{cite journal |author=Martinez-Rumayor A, Januzzi JL |title=Non-ST segment elevation acute coronary syndromes: A comprehensive review |journal=[[Southern Medical Journal]] |volume=99 |issue=10 |pages=1103–10 |year=2006 |month=October |pmid=17100031 |doi= |url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0038-4348&volume=99&issue=10&spage=1103 |accessdate=2011-04-11}}</ref> This plaque rupture exposes ligands (including collagen) for platelet adhesion which causes platelet aggregation and subsequent platelet activation. <ref name="pmid9296464">{{cite journal |author=Patrono C, Renda G |title=Platelet activation and inhibition in unstable coronary syndromes |journal=[[The American Journal of Cardiology]] |volume=80 |issue=5A |pages=17E–20E |year=1997 |month=September |pmid=9296464 |doi= |url= |accessdate=2011-04-11}}</ref> [[Platelets]] are activated by [[thrombin]] (found in blood clots), [[adenosine diphosphate]] (found in platelet granules), [[serotonin]] (also found in platelet granules) and thromboxane-A2. <ref name="pmid9296464">{{cite journal |author=Patrono C, Renda G |title=Platelet activation and inhibition in unstable coronary syndromes |journal=[[The American Journal of Cardiology]] |volume=80 |issue=5A |pages=17E–20E |year=1997 |month=September |pmid=9296464 |doi= |url= |accessdate=2011-04-11}}</ref> Upon activation, the [[glycoprotein IIb/IIIa]] receptor that in a non-active state is found in the cytosol is exteriorized and modified which enables additional platelet aggregation and cross-linking.<ref name="pmid17100031">{{cite journal |author=Martinez-Rumayor A, Januzzi JL |title=Non-ST segment elevation acute coronary syndromes: A comprehensive review |journal=[[Southern Medical Journal]] |volume=99 |issue=10 |pages=1103–10 |year=2006 |month=October |pmid=17100031 |doi= |url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0038-4348&volume=99&issue=10&spage=1103 |accessdate=2011-04-11}}</ref> The prothrombinase complex then binds to the activated platelet and starts to [[coagulation cascade]].<ref name="pmid17100031">{{cite journal |author=Martinez-Rumayor A, Januzzi JL |title=Non-ST segment elevation acute coronary syndromes: A comprehensive review |journal=[[Southern Medical Journal]] |volume=99 |issue=10 |pages=1103–10 |year=2006 |month=October |pmid=17100031 |doi= |url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0038-4348&volume=99&issue=10&spage=1103 |accessdate=2011-04-11}}</ref> This entire process results in a thrombus which coalesces over the ruptured plaque. | ||
Below is the animation showing clot formation which breaks off to embolize artery downstream | '''Below is the animation showing clot formation which breaks off to embolize artery downstream:''' | ||
<youtube v=T_t-0cAP1C4/> | <youtube v=T_t-0cAP1C4/> | ||
<br clear="left"/> | |||
[[Image:Coronary thrombosis 3.jpg|350px|left|thumb|Plaque rupture in a coronary artery at arrows yielding obstructive thrombus in red.]] | |||
<br clear="left"/> | |||
Although less common, ACS may also occur by other mechanisms. These include: | |||
Although less common, ACS may also occur by other mechanisms. These include | |||
* coronary artery spasm as in [[Prinzmetal's angina]], | * coronary artery spasm as in [[Prinzmetal's angina]], | ||
| Line 27: | Line 27: | ||
* secondary ischemia in cases in which there is either increased myocardial oxygen demand as in tachycardia from fever, [[anemia]], [[hypoxemia]], [[thyrotoxicosis]], or in cases of decreased supply such as in hypotension or anemia from hemorrhage. | * secondary ischemia in cases in which there is either increased myocardial oxygen demand as in tachycardia from fever, [[anemia]], [[hypoxemia]], [[thyrotoxicosis]], or in cases of decreased supply such as in hypotension or anemia from hemorrhage. | ||
==Genetics== | |||
To date, there does not appear to be any single genetic marker predictive acute coronary syndrome (ACS).<ref name="pmid17239708">{{cite journal |author=Anwaruddin S, Askari AT, Topol EJ |title=Redefining risk in acute coronary syndromes using molecular medicine |journal=[[Journal of the American College of Cardiology]] |volume=49 |issue=3 |pages=279–89 |year=2007 |month=January |pmid=17239708 |doi=10.1016/j.jacc.2006.08.051 |url=http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(06)02637-4 |accessdate=2011-04-11}}</ref> In a recent validation study of genetic variants associated with (which includes [[STEMI]], [[NSTEMI]] and [[UA]]) none of the 85 genetic variants tested were shown to be correlated with ACS. The study chose the polymorphic genetic variants based on statistically significant findings of prior studies. <ref name="pmid17426274">{{cite journal |author=Morgan TM, Krumholz HM, Lifton RP, Spertus JA |title=Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study |journal=[[JAMA : the Journal of the American Medical Association]] |volume=297 |issue=14 |pages=1551–61 |year=2007 |month=April |pmid=17426274 |doi=10.1001/jama.297.14.1551 |url=http://jama.ama-assn.org/cgi/pmidlookup?view=long&pmid=17426274 |accessdate=2011-04-11}}</ref> Nonetheless, although no individual marker is likely to be predictive, in the future it is possible that a panel of markers may be used to assess risk.<ref name="pmid17239708">{{cite journal |author=Anwaruddin S, Askari AT, Topol EJ |title=Redefining risk in acute coronary syndromes using molecular medicine |journal=[[Journal of the American College of Cardiology]] |volume=49 |issue=3 |pages=279–89 |year=2007 |month=January |pmid=17239708 |doi=10.1016/j.jacc.2006.08.051 |url=http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(06)02637-4 |accessdate=2011-04-11}}</ref> <ref name="pmid12889664">{{cite journal |author=Wilcken DE |title=Overview of inherited metabolic disorders causing cardiovascular disease |journal=[[Journal of Inherited Metabolic Disease]] |volume=26 |issue=2-3 |pages=245–57 |year=2003 |pmid=12889664 |doi= |url=http://www.kluweronline.com/art.pdf?issn=0141-8955&volume=26&page=245 |accessdate=2011-04-11}}</ref> | To date, there does not appear to be any single genetic marker predictive acute coronary syndrome (ACS).<ref name="pmid17239708">{{cite journal |author=Anwaruddin S, Askari AT, Topol EJ |title=Redefining risk in acute coronary syndromes using molecular medicine |journal=[[Journal of the American College of Cardiology]] |volume=49 |issue=3 |pages=279–89 |year=2007 |month=January |pmid=17239708 |doi=10.1016/j.jacc.2006.08.051 |url=http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(06)02637-4 |accessdate=2011-04-11}}</ref> In a recent validation study of genetic variants associated with (which includes [[STEMI]], [[NSTEMI]] and [[UA]]) none of the 85 genetic variants tested were shown to be correlated with ACS. The study chose the polymorphic genetic variants based on statistically significant findings of prior studies. <ref name="pmid17426274">{{cite journal |author=Morgan TM, Krumholz HM, Lifton RP, Spertus JA |title=Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study |journal=[[JAMA : the Journal of the American Medical Association]] |volume=297 |issue=14 |pages=1551–61 |year=2007 |month=April |pmid=17426274 |doi=10.1001/jama.297.14.1551 |url=http://jama.ama-assn.org/cgi/pmidlookup?view=long&pmid=17426274 |accessdate=2011-04-11}}</ref> Nonetheless, although no individual marker is likely to be predictive, in the future it is possible that a panel of markers may be used to assess risk.<ref name="pmid17239708">{{cite journal |author=Anwaruddin S, Askari AT, Topol EJ |title=Redefining risk in acute coronary syndromes using molecular medicine |journal=[[Journal of the American College of Cardiology]] |volume=49 |issue=3 |pages=279–89 |year=2007 |month=January |pmid=17239708 |doi=10.1016/j.jacc.2006.08.051 |url=http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(06)02637-4 |accessdate=2011-04-11}}</ref> <ref name="pmid12889664">{{cite journal |author=Wilcken DE |title=Overview of inherited metabolic disorders causing cardiovascular disease |journal=[[Journal of Inherited Metabolic Disease]] |volume=26 |issue=2-3 |pages=245–57 |year=2003 |pmid=12889664 |doi= |url=http://www.kluweronline.com/art.pdf?issn=0141-8955&volume=26&page=245 |accessdate=2011-04-11}}</ref> | ||
| Line 68: | Line 68: | ||
== References == | == References == | ||
{{Reflist}} | {{Reflist|2}} | ||
==See Also== | ==See Also== | ||
* [[The Living Guidelines: UA/NSTEMI]] | * [[The Living Guidelines: UA/NSTEMI]] | ||
{{Electrocardiography}} | {{Electrocardiography}} | ||
{{Circulatory system pathology}} | {{Circulatory system pathology}} | ||
[[Category:Cardiology]] | [[Category:Cardiology]] | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Revision as of 04:23, 8 July 2011
|
Unstable angina / NSTEMI Microchapters |
|
Differentiating Unstable Angina/Non-ST Elevation Myocardial Infarction from other Disorders |
|
Special Groups |
|
Diagnosis |
|
Laboratory Findings |
|
Treatment |
|
Antitplatelet Therapy |
|
Additional Management Considerations for Antiplatelet and Anticoagulant Therapy |
|
Risk Stratification Before Discharge for Patients With an Ischemia-Guided Strategy of NSTE-ACS |
|
Mechanical Reperfusion |
|
Discharge Care |
|
Case Studies |
|
Non ST elevation myocardial infarction pathophysiology On the Web |
|
FDA on Non ST elevation myocardial infarction pathophysiology |
|
CDC onNon ST elevation myocardial infarction pathophysiology |
|
Non ST elevation myocardial infarction pathophysiology in the news |
|
Blogs on Non ST elevation myocardial infarction pathophysiology |
|
to Hospitals Treating Non ST elevation myocardial infarction pathophysiology |
|
Risk calculators and risk factors for Non ST elevation myocardial infarction pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Varun Kumar, M.B.B.S.; Lakshmi Gopalakrishnan, M.B.B.S.
NSTEMI Background
As alluded to in prior sections, Unstable Angina and NSTEMI are at different ends of the spectrum of the same disease. While there is no way to determine which patients presenting with Unstable Angina will ultimately progress to NSTEMI, the distinction between the two entities is clear. Often, for patients presenting prior to the four hour window before cardiac biomarkers are positive (namely CK-MB), the EKG in context of the patient's chest pain will be marker for whether patient has STEMI versus UA/NSTEMI and needs to urgently undergo percutaneous revascularization.
Plaque rupture, thrombus formation, and embolization underly the pathophysiology of NSTEMI
This video shows plaque rupture or disruption of the atherosclerotic plaque in the mid LAD. As is often the case, the plaque has torn at its edge, a location where the fibrous cap covering the atherosclerotic plaque is the thinnest. Clot has formed and it is embolizing downstream. The most common preceding pathophysiologic event in NSTEMI is the disruption of an atherosclerotic plaque in an epicardial coronary artery such as that shown here. Exposure of the atherosclerotic plaque contents to the blood stream leads to activation of the clotting cascade, local thrombus formation, and incomplete occlusion of the epicardial artery in NSTEMI. This artery is open, in NSTEMI unlike STEMI where the artery is closed. The downstream microvasculature is occluded by the clot that has embolized, and this accounts for the troponin elevation in this patient.
As opposed to the original hypothesis that acute coronary syndrome (ACS) is caused by gradual progression of coronary atherosclerosis to the point of a severe, fixed lesion, it has become clear that, in fact, ACS is usually caused by atherosclerotic plaque rupture at a site that previously had only mild to moderate stenosis.[1] This plaque rupture exposes ligands (including collagen) for platelet adhesion which causes platelet aggregation and subsequent platelet activation. [2] Platelets are activated by thrombin (found in blood clots), adenosine diphosphate (found in platelet granules), serotonin (also found in platelet granules) and thromboxane-A2. [2] Upon activation, the glycoprotein IIb/IIIa receptor that in a non-active state is found in the cytosol is exteriorized and modified which enables additional platelet aggregation and cross-linking.[1] The prothrombinase complex then binds to the activated platelet and starts to coagulation cascade.[1] This entire process results in a thrombus which coalesces over the ruptured plaque.
Below is the animation showing clot formation which breaks off to embolize artery downstream:
<youtube v=T_t-0cAP1C4/>
Although less common, ACS may also occur by other mechanisms. These include:
- coronary artery spasm as in Prinzmetal's angina,
- severe narrowing alone without plaque rupture, as in the case of restenosis after percutaneous coronary intervention (PCI) or as with progressive atherosclerosis,
- coronary artery dissection,
- secondary ischemia in cases in which there is either increased myocardial oxygen demand as in tachycardia from fever, anemia, hypoxemia, thyrotoxicosis, or in cases of decreased supply such as in hypotension or anemia from hemorrhage.
Genetics
To date, there does not appear to be any single genetic marker predictive acute coronary syndrome (ACS).[3] In a recent validation study of genetic variants associated with (which includes STEMI, NSTEMI and UA) none of the 85 genetic variants tested were shown to be correlated with ACS. The study chose the polymorphic genetic variants based on statistically significant findings of prior studies. [4] Nonetheless, although no individual marker is likely to be predictive, in the future it is possible that a panel of markers may be used to assess risk.[3] [5]
Complete List of (known) Underlying Mechanisms of NSTEMI
- Inflammation
- Leukocytes, platelets
- Plaque disruption or plaque erosion
- Thrombosis
List of Factors may Effect Development and Complications of NSTEMI
(In alphabetical order)
- Blood lipid levels
- Catecholamine levels (smoking, cocaine, stress)
- Degree of coronary vasoconstriction
- Endothelial function
- Extent of collaterals
- Extent of plaque rupture or erosion
- Inflammatory substrate
- Location of the culprit coronary lesion
- Microembolization and microvascular obstruction
- Stenosis morphology and severity
- Systemic factors
- Heart rate and blood pressure
- Thrombotic factors
- Blood viscosity
- Intrinsic clotting activity
- Leukocyte activation
- Level of fibrinolytic activity
- Plaque tissue factor levels
- Platelet aggregability and reactivity
References
- ↑ 1.0 1.1 1.2 Martinez-Rumayor A, Januzzi JL (2006). "Non-ST segment elevation acute coronary syndromes: A comprehensive review". Southern Medical Journal. 99 (10): 1103–10. PMID 17100031. Retrieved 2011-04-11. Unknown parameter
|month=ignored (help) - ↑ 2.0 2.1 Patrono C, Renda G (1997). "Platelet activation and inhibition in unstable coronary syndromes". The American Journal of Cardiology. 80 (5A): 17E–20E. PMID 9296464. Unknown parameter
|month=ignored (help);|access-date=requires|url=(help) - ↑ 3.0 3.1 Anwaruddin S, Askari AT, Topol EJ (2007). "Redefining risk in acute coronary syndromes using molecular medicine". Journal of the American College of Cardiology. 49 (3): 279–89. doi:10.1016/j.jacc.2006.08.051. PMID 17239708. Retrieved 2011-04-11. Unknown parameter
|month=ignored (help) - ↑ Morgan TM, Krumholz HM, Lifton RP, Spertus JA (2007). "Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study". JAMA : the Journal of the American Medical Association. 297 (14): 1551–61. doi:10.1001/jama.297.14.1551. PMID 17426274. Retrieved 2011-04-11. Unknown parameter
|month=ignored (help) - ↑ Wilcken DE (2003). "Overview of inherited metabolic disorders causing cardiovascular disease" (PDF). Journal of Inherited Metabolic Disease. 26 (2–3): 245–57. PMID 12889664. Retrieved 2011-04-11.